← Back to Ipca Laboratories Ltd. overview
Ipca Laboratories Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹8,855 cr | ₹738 cr | ₹29.08 | ₹11,761 cr | ₹6,948 cr | 10.62% | 14.62% | 0.2x | 8.33% |
| FY2024 | ₹7,622 cr | ₹547 cr | ₹21.57 | ₹11,101 cr | ₹6,332 cr | 8.64% | 12.61% | 0.23x | 7.18% |
| FY2023 | ₹6,207 cr | ₹471 cr | ₹18.58 | ₹8,626 cr | ₹5,842 cr | 8.07% | 10.79% | 0.25x | 7.59% |
| FY2022 | ₹5,766 cr | ₹884 cr | ₹34.85 | ₹7,624 cr | ₹5,464 cr | 16.18% | 18.23% | 0.15x | 15.33% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.